Dhaval Mehta

Patient preference for subcutaneous vs. intravenous immune therapy (PSI-Immune).

Vincent Reyes, Jennifer Ruth, Hong Wang, Nishant Tageja et autres

TPS1678 Background: Immune checkpoint blockade (ICB) has improved outcomes for patients (pts) with advanced solid tumors. Conventional intravenous (IV) route of administration (RoA) requires repeated, time-intensive infusions involving cannulation, monitoring, pharmacy preparation, and chair time, increasing treatment burden and constraining infusion center …

us (code pays fourni par la source)

A randomized prospective trial evaluating duration of PD-1 and PD-L1 inhibitor therapy in advanced solid tumors.

Vincent Reyes, Ryan Sweeney, Mark Jelinek, Hong Wang et autres

2514 Background: Immune checkpoint inhibitors (IO) have revolutionized the treatment of advanced solid tumors. Despite their widespread adoption, the optimal duration of IO has not been clearly established, and this remains an unmet clinical need. Methods: In our prospective trial, patients (pts) …

us (code pays fourni par la source)

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir J. Choksi et autres

Abstract Background: The University of Pittsburgh Medical Center (UPMC) partnered with IntegraConnect to conduct a quality initiative (QI) studying the utilization of anti-CD38 agents and quadruplet (quad) therapy (lenalidomide, CD38, proteasome inhibitor and dexamethasone) in newly diagnosed multiple myeloma (NDMM), and how …

us, ca (code pays fourni par la source)

S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).

Sukhmani K. Padda, Mary W. Redman, David E. Gerber, Katherine Minichiello et autres

8518 Background: In previously treated KRAS G12C MUT NSCLC, the allosteric KRAS G12C inhibitor sotorasib had superior outcomes compared to docetaxel (ORR 28% vs 13%). S1900E was the first to prospectively test sotorasib in KRAS G12C MUT NSCLC according to co-mutations (CO-MUT) …

us (code pays fourni par la source)

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced Cancer: A Randomized Clinical Trial

Yael Schenker, Shane Belin, Tianxiu Wang, Rebecca L. Sudore et autres

PURPOSE Guidelines recommend advance care planning (ACP) to improve patient-centered care near the end of life (EOL), but the optimal approach is unknown. This single-blind, patient-level, randomized comparative effectiveness trial compared two patient-facing ACP interventions that are widely used but differ in …

us (code pays fourni par la source)

A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).

Jennifer R. Eads, Noah Graham, Michael K. Gibson, Lakshmi Rajdev et autres

4000 Background: E/GEJ adenocarcinoma has a high mortality rate despite curative intent therapy. Although the use of immune checkpoint inhibition (ICI) in combination with chemotherapy in the metastatic setting and as adjuvant monotherapy both confer survival benefits, its role in combination with …

us (code pays fourni par la source)

A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2

Khvaramze Shaverdashvili, Vincent Reyes, Hong Wang, Dhaval Mehta et autres

Background: Approximately 30-40% of patients with advanced and metastatic non-small cell lung cancer (NSCLC) present with an impaired performance status (PS). There are limited prospective data on the safety and efficacy of durvalumab in these patients. Methods: In this single-arm phase II …

us (code pays fourni par la source)

A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab as First Line Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer Patients with Eastern Cooperative Oncology Group Performance Status of 2

Khvaramze Shaverdashvili, Vincent Reyes, Hong Wang, Dhaval Mehta et autres

us (code pays fourni par la source)

A longitudinal surgical systems strengthening research program for medical students: the exploration of a model for global health education

Gregory Peck, Joseph Hanna, Erin M. Scott, Dhaval Mehta et autres

BACKGROUND: In response to the staggering global burden of conditions requiring emergency and essential surgery, the development of international surgical system strengthening (SSS) is fundamental to achieving universal, timely, quality, and affordable surgical care. Opportunity exists in identifying optimal collaborative processes that …

us, nl, co (code pays fourni par la source)

Latin America Indicator Research Coalition examines prehospital care using a trauma systems application of LCoGS indicator 1.

Gregory Peck, David Blitzer, Isabelle Citron, John Dutton et autres

Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.

Ahmad A. Tarhini, Imran Rafique, Phu N. Tran, William E. Gooding et autres

8092 Background: MET is frequently overexpressed in NSCLC. Amplification of MET and its ligand (HGF), are mechanisms of resistance to EGFR inhibitors. R is an IgG2 human mAb that targets HGF. This phase I/II trial evaluated the safety and recommended phase 2 …

us (code pays fourni par la source)

COMPARISON BETWEEN GEL CARD AND CONVENTIONAL DIRECT COOMBS TEST FOR DIAGNOSIS OF AUTOIMMUNE HAEMOLYTIC ANAEMIA

Sameep Garg, Dhaval Mehta, Nandini Desai, JitendraH Vachhani

Background: The diagnosis of autoimmune hemolytic anemia (AIHA) requires the establishment of hemolysis and demonstration of autoantibodies against red cells. Most laboratories use the conventional Coomb's test for the demonstration of the autoantibodies. However, in approximately 4-8% of the patients who present …

in (code pays fourni par la source)